Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma - 14/05/14
Abstract |
Background |
Accurate assessment of prognosis remains clinically challenging in stage II to III cutaneous melanoma. Studies have implicated CD2 in immune surveillance, T-cell activation, and antitumor immunity, but its role in melanoma progression warrants further investigation.
Objective |
We sought to investigate the prognostic role of CD2 in primary cutaneous melanoma.
Methods |
Patients with American Joint Committee on Cancer stage II and III cutaneous melanoma were identified by retrospective review of dermatopathology databases from 2001 to 2010 at Mount Sinai Medical Center and Geisinger Medical Center. Additional patients were provided by New York University Medical Center based on retrospective review and tissue availability. Immunohistochemistry was performed on tumors from 90 patients with known recurrence status and documented follow-up.
Results |
Primary tumors from patients who developed recurrent disease had fewer CD2+ cells (P = .0003). In multivariable analyses including standard clinicopathologic predictors, CD2 was an independent predictor of disease recurrence (P = .008) and overall survival (P = .007). CD2 count correlated with characterization of tumor-infiltrating lymphocytes (P = .0004). Among the intermediate prognosis group of patients with nonbrisk tumor-infiltrating lymphocytes, CD2 count was predictive of disease recurrence (P = .0006) and overall survival (P = .0318).
Limitations |
Our retrospective design may have resulted in incomplete representation of patients lacking documented follow-up.
Conclusions |
CD2 may be an independent predictor of disease recurrence and overall survival among patients with primary cutaneous melanoma.
Le texte complet de cet article est disponible en PDF.Key words : biomarker, melanoma, primary melanoma, prognosis, recurrence, survival, tumor-infiltrating lymphocytes
Abbreviations used : AJCC, HPF, IHC, MSMC, NK, TILs
Plan
| Supplemental figures and table are available at www.jaad.org/. |
|
| Funded in part by Medical Student Research grants from the American Skin Association and the Melanoma Research Foundation to Ms Harcharik and by a Career Development Award from the Dermatology Foundation to Dr Saenger. |
|
| Disclosure: Drs Saenger, S. Sivendran, and Chang hold a pending patent for a molecular signature including CD2. Ms Harcharik; Drs Bernardo, M. Sivendranm, Hall, Castillo-Martín, Cordon-Cardo, and Phelps; Ms Moskalenko; Mr Pan; Ms Bell; and Ms Fox have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 70 - N° 6
P. 1036 - juin 2014 Retour au numéro
Article précédent
- Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma
- Matthew E. Johnson, Fang Zhu, Tianyu Li, Hong Wu, Thomas J. Galloway, Jeffrey M. Farma, Clifford S. Perlis, Aruna Turaka
- Atenolol versus propranolol for the treatment of infantile hemangiomas: A randomized controlled study
- Álvaro Abarzúa-Araya, Cristián P. Navarrete-Dechent, Felipe Heusser, Javiera Retamal, María Soledad Zegpi-Trueba
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?